Wikipedia

Lulizumab pegol

Lulizumab pegol (INN;[1] development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases.[2]

Lulizumab pegol
Monoclonal antibody
Type?
SourceHumanized
Targetglycoprotein CD28
Clinical data
Other namesBMS-931699
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC552H859N149O164S4
Molar mass12335.06 g·mol−1

This drug was developed by Bristol-Myers Squibb.

References

edit
  1. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol, American Medical Association.
 

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lulizumab_pegol&oldid=1235160760"